|3.80||+0.0600||+1.60%||Vol 280.86K||1Y Perf 40.71%|
|Sep 23rd, 2021 12:55 DELAYED|
|- -%||- -|
|Target Price||6.64||Analyst Rating||Strong Buy 1.00|
|Potential %||76.13||Finscreener Ranking||★★★★★ 62.89|
|Insiders Trans % 3/6/12 mo.||-100/-100/-90||Value Ranking||★★★★ 57.08|
|Insiders Value % 3/6/12 mo.||-100/-100/-98||Growth Ranking||★★★★★ 81.89|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-97||Income Ranking||— -|
|Price Range Ratio 52W %||47.95||Earnings Rating||Sell|
|Market Cap||645.88M||Earnings Date||4th Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Nov 2021|
|Estimated EPS Next Report||0.03|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||682.15K|
|Avg. Monthly Volume||568.78K|
|Avg. Quarterly Volume||659.72K|
Antares Pharma Inc. (NASDAQ: ATRS) stock closed at 3.74 per share at the end of the most recent trading day (a 1.08% change compared to the prior day closing price) with a volume of 466.17K shares and market capitalization of 645.88M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 178 people. Antares Pharma Inc. CEO is Robert F. Apple.
The one-year performance of Antares Pharma Inc. stock is 40.71%, while year-to-date (YTD) performance is -6.27%. ATRS stock has a five-year performance of 125.3%. Its 52-week range is between 2.63 and 5.07, which gives ATRS stock a 52-week price range ratio of 47.95%
Antares Pharma Inc. currently has a PE ratio of 9.80, a price-to-book (PB) ratio of 4.81, a price-to-sale (PS) ratio of 3.64, a price to cashflow ratio of 31.90, a PEG ratio of 2.32, a ROA of 37.43%, a ROC of 52.53% and a ROE of 70.70%. The company’s profit margin is 39.20%, its EBITDA margin is 15.90%, and its revenue ttm is $171.20 Million , which makes it $1.01 revenue per share.
Of the last four earnings reports from Antares Pharma Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.03 for the next earnings report. Antares Pharma Inc.’s next earnings report date is 04th Nov 2021.
The consensus rating of Wall Street analysts for Antares Pharma Inc. is Strong Buy (1), with a target price of $6.64, which is +76.13% compared to the current price. The earnings rating for Antares Pharma Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Antares Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Antares Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.96, ATR14 : 0.12, CCI20 : -41.87, Chaikin Money Flow : -0.10, MACD : -0.09, Money Flow Index : 35.03, ROC : -4.59, RSI : 43.80, STOCH (14,3) : 45.24, STOCH RSI : 1.00, UO : 48.37, Williams %R : -54.76), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Antares Pharma Inc. in the last 12-months were: Anton G. Gueth (Option Excercise at a value of $187 031), Anton G. Gueth (Sold 100 000 shares of value $429 000 ), Fred M. Powell (Buy at a value of $46 740), Leonard S. Jacob (Option Excercise at a value of $68 638), Leonard S. Jacob (Sold 30 642 shares of value $154 742 ), Peter J. Graham (Option Excercise at a value of $50 400), Peter J. Graham (Sold 45 000 shares of value $221 650 ), Robert F. Apple (Option Excercise at a value of $470 210), Robert F. Apple (Sold 587 460 shares of value $2 913 603 ), Thomas J. Garrity (Option Excercise at a value of $425 600), Thomas J. Garrity (Sold 340 000 shares of value $1 457 800 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.